BRACAnalysis ® is a genetic test that detects the presence of a BRCA1 or BRCA2 gene mutation. BRCA mutations are responsible for the majority of hereditary breast and ovarian cancers. People with a mutation in either the BRCA1 or BRCA2 gene have risks of up to 87 percent for developing breast cancer and 39-63 percent for developing ovarian cancer by age 70. Mutation carriers previously diagnosed with cancer also have a significantly increased risk of developing a second primary cancer. In fact, patients with these types of mutations have an up to 64 percent chance of developing a second breast cancer by age 70.
BRACAnalysis requires only a simple blood test or oral rinse sample to determine if a person has a BRCA1 or BRCA2 mutation. Knowing the results may help patients and their healthcare professionals either prevent or delay the onset of cancer or detect it at an earlier, more treatable stage.
Myriad has developed a Hereditary Cancer Quiz that patients and can use to help identify potential candidates for genetic testing using BRACAnalysis.
The results of the BRACAnalysis test enable the development of patient-specific medical management plans to significantly reduce the risk of cancer. BRACAnalysis allows healthcare professionals to:
If BRACAnalysis testing confirms the presence of a BRCA1 or BRCA2 mutation, the following medical management options may help reduce cancer risk and may either delay the onset of cancer, detect it at an earlier, more treatable stage or may even prevent it:
NOTE: Any discussion of medical management options is for general informational purposes only and does not constitute a recommendation. While genetic testing and medical society guidelines provide important and useful information, medical management decisions should be made based on consultation between each patient and his or her healthcare professional.
For more healthcare professional information, please visit MyriadPro.com.
Myriad Genetics First Quarter 2022 Financial Results Conference Call